Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cytek Biosciences, Inc.NASDAQ: CTKB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $2.81M fell 2.5% year over year, behind the +9.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.6% from the prior quarter. Over 3 fiscal years it compounded at +28.4% a year.
Context
- Depreciation & amortization amounted to 5.9% of revenue in FY2025, up 0.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.5% toward the trailing-twelve-month pace of +9.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 11.98M USD
- Year-over-year change
- +14.2%
- 4-year CAGR
- +76.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.98M | +14.2% |
| FY2024 | 2024-12-31 | 10.49M | +13.7% |
| FY2023 | 2023-12-31 | 9.23M | +63.1% |
| FY2022 | 2022-12-31 | 5.66M | +355.6% |
| FY2021 | 2021-12-31 | 1.24M | — |
Depreciation & Amortization vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's LTM Mar 2026 depreciation & amortization of $11.9M is the 5th largest of the 6 companies compared; the peer median is $127.6M.
- Its year-over-year change of +9.1% is the 3rd highest of 6, against a peer median of -5.2%.
- Depreciation & amortization amounts to 5.8% of revenue for CTKB, versus a peer median of 6.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $271M | -5.2% | -3.1% | 3.7% | |
| LTM Jun 2026 | $230.1M | +9.4% | +35.4% | 6.6% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Jun 2026 | $45.93M | +12.6% | +9.9% | 7.4% | |
| LTM Mar 2026 | $11.9M | +9.1% | +28.4% | 5.8% | |
| LTM Mar 2026 | $10.99M | -30.6% | -51.5% | 12.7% | |
| Peer median (excluding CTKB) | $127.6M | -5.2% | +6.4% | 6.6% | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.03M | 2.48M | (12.15M) | (6.02M) | (66.54M) |
| Depreciation & Amortization | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| Deferred Income Tax | 0 | 0 | 0 | (2.89M) | 33.56M |
| Stock-Based Compensation | 6.59M | 16.6M | 22.05M | 26.85M | 24.59M |
| Change in Working Capital | (8.65M) | (39.93M) | (10.51M) | 7.71M | (4.79M) |
| Accounts Receivables | (12.37M) | (19.74M) | (7.33M) | (5.43M) | 368K |
| Inventory | (7.07M) | (17.65M) | 4.29M | 14.76M | (5.24M) |
| Accounts Payables | (256K) | 1.86M | (1.78M) | 2.58M | 448K |
| Other Working Capital | 11.05M | (4.39M) | (5.68M) | (4.2M) | (366K) |
| Other Non-Cash Items | 2.42M | 2.96M | (3.34M) | (10.77M) | (3.47M) |
| Operating Cash Flow | 4.63M | (12.23M) | 5.28M | 25.38M | (4.69M) |
| Capital Expenditures | (4.36M) | (9.87M) | (4.83M) | (3.53M) | (4.08M) |
| Acquisitions (Net) | (16.63M) | 0 | (45.13M) | (471K) | 252K |
| Purchases of Investments | 0 | (46.04M) | (175.94M) | (274.06M) | (278.16M) |
| Sales of Investments | 0 | 0 | 132M | 195M | 292.21M |
| Other Investing Activities | 0 | (120K) | (179K) | 84K | (107K) |
| Investing Cash Flow | (20.99M) | (55.91M) | (93.89M) | (82.97M) | 10.12M |
| Debt Repayment | (2.77M) | 2.93M | (565K) | 3.62M | 837K |
| Common Stock Issued | 215.69M | 2.79M | 0 | 0 | 1.47M |
| Common Stock Repurchased | 0 | 0 | (44.15M) | (21.61M) | (15.07M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 642K | (209K) | 2.9M | 2.17M | (669K) |
| Financing Cash Flow | 213.56M | 5.51M | (41.81M) | (15.82M) | (13.43M) |
| Effect of Forex Changes | 1.3M | (2.49M) | (1.45M) | 4.53M | 109K |
| Net Change in Cash | 198.5M | (65.12M) | (131.87M) | (68.89M) | (7.89M) |
| Free Cash Flow | 266K | (22.1M) | 454K | 21.85M | (8.77M) |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.